CR20200454A - Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso - Google Patents

Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso

Info

Publication number
CR20200454A
CR20200454A CR20200454A CR20200454A CR20200454A CR 20200454 A CR20200454 A CR 20200454A CR 20200454 A CR20200454 A CR 20200454A CR 20200454 A CR20200454 A CR 20200454A CR 20200454 A CR20200454 A CR 20200454A
Authority
CR
Costa Rica
Prior art keywords
compounds
methods
same
differentiation factor
agonist compounds
Prior art date
Application number
CR20200454A
Other languages
English (en)
Inventor
Victor H Obungu
Richard Todd Pickard
Malgorzata Donata Gonciarz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20200454A publication Critical patent/CR20200454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>Se proporcionan en la presente compuestos que inducen pérdida de peso y que tratan la diabetes, dislipidemia, NASH y/u obesidad. También se proporcionan composiciones farmacéuticas que contienen dichos compuestos y usos terapéuticos de tales compuestos y composiciones, en donde dichos compuestos actúan como agonistas de GDF15 con un tiempo de acción prolongado y otras propiedades ventajosas.</p>
CR20200454A 2018-04-06 2019-03-29 Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso CR20200454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653759P 2018-04-06 2018-04-06
PCT/US2019/024756 WO2019195091A1 (en) 2018-04-06 2019-03-29 Growth differentiation factor 15 agonist compounds and methods of using the same

Publications (1)

Publication Number Publication Date
CR20200454A true CR20200454A (es) 2020-11-18

Family

ID=66630339

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200454A CR20200454A (es) 2018-04-06 2019-03-29 Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso

Country Status (27)

Country Link
US (1) US11104711B2 (es)
EP (1) EP3774860B1 (es)
JP (1) JP7064618B2 (es)
KR (1) KR102501922B1 (es)
CN (1) CN112004821B (es)
AR (1) AR115021A1 (es)
AU (1) AU2019248535B2 (es)
BR (1) BR112020017256A2 (es)
CA (1) CA3096375C (es)
CL (1) CL2020002564A1 (es)
CO (1) CO2020012403A2 (es)
CR (1) CR20200454A (es)
DO (1) DOP2020000157A (es)
EA (1) EA202092084A1 (es)
EC (1) ECSP20062930A (es)
ES (1) ES2937049T3 (es)
IL (1) IL276980A (es)
JO (1) JOP20200252B1 (es)
MA (1) MA52228A (es)
MX (1) MX2020010370A (es)
PE (1) PE20212133A1 (es)
PH (1) PH12020551656A1 (es)
SG (1) SG11202009853VA (es)
TW (1) TWI724392B (es)
UA (1) UA127545C2 (es)
WO (1) WO2019195091A1 (es)
ZA (1) ZA202005385B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
PT3027642T (pt) 2013-07-31 2020-10-30 Amgen Inc Construtos do fator 15 de diferenciação de crescimento (gdf-15)
AU2019253462A1 (en) 2018-04-09 2020-11-26 Amgen Inc. Growth differentiation factor 15 fusion proteins
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
KR20240049337A (ko) 2021-08-24 2024-04-16 선샤인 레이크 파르마 컴퍼니 리미티드 Gdf15 융합 단백질 및 이의 용도
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
EP2571510B1 (en) * 2010-05-21 2018-08-08 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
US9732143B2 (en) * 2011-02-03 2017-08-15 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA2896076C (en) * 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
CN105658664A (zh) 2013-07-31 2016-06-08 美国安进公司 含有Fc的多肽的稳定化
PT3027642T (pt) 2013-07-31 2020-10-30 Amgen Inc Construtos do fator 15 de diferenciação de crescimento (gdf-15)
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
CN106459222A (zh) 2014-06-24 2017-02-22 诺和诺德股份有限公司 Mic‑1融合蛋白及其用途
CN106573966B (zh) 2014-07-30 2022-03-01 Ngm生物制药有限公司 用于治疗代谢异常的组合物和方法
CA2964808C (en) 2014-10-30 2023-06-27 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
MD20170035A2 (ro) * 2014-10-31 2017-09-30 Ngm Biopharmaceuticals Inc Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
EP3277304B1 (en) 2015-04-02 2021-08-04 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
JP6946304B2 (ja) * 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
BR112018076290A2 (pt) 2016-02-29 2019-11-12 Huawei Tech Co Ltd método de otimização de video, equipamento do usuário, dispositivo de rede e meio legível por computador
WO2017147742A1 (en) 2016-02-29 2017-09-08 Eli Lilly And Company Gfral receptor therapies
JP2019513224A (ja) 2016-03-04 2019-05-23 エヌジーエム バイオファーマシューティカルス，インコー 体重を調節するための組成物及び方法
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
KR102501922B1 (ko) 2023-02-23
CN112004821A (zh) 2020-11-27
MA52228A (fr) 2021-02-17
UA127545C2 (uk) 2023-10-04
AU2019248535A1 (en) 2020-09-10
KR20200128091A (ko) 2020-11-11
MX2020010370A (es) 2021-01-08
AU2019248535B2 (en) 2021-09-02
DOP2020000157A (es) 2020-09-15
ES2937049T3 (es) 2023-03-23
TW201946661A (zh) 2019-12-16
CO2020012403A2 (es) 2020-10-30
ZA202005385B (en) 2022-09-28
JP2021517584A (ja) 2021-07-26
PE20212133A1 (es) 2021-11-05
IL276980A (en) 2020-10-29
EP3774860B1 (en) 2022-12-28
CN112004821B (zh) 2024-01-02
EA202092084A1 (ru) 2021-01-27
CL2020002564A1 (es) 2021-01-29
WO2019195091A1 (en) 2019-10-10
US11104711B2 (en) 2021-08-31
JOP20200252A1 (ar) 2020-10-04
AR115021A1 (es) 2020-11-18
PH12020551656A1 (en) 2021-07-26
JP7064618B2 (ja) 2022-05-10
CA3096375C (en) 2023-09-12
EP3774860A1 (en) 2021-02-17
CA3096375A1 (en) 2019-10-10
ECSP20062930A (es) 2020-11-30
SG11202009853VA (en) 2020-11-27
JOP20200252B1 (ar) 2023-09-17
TWI724392B (zh) 2021-04-11
BR112020017256A2 (pt) 2020-12-22
US20190309033A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
CR20200454A (es) Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
PH12020551304A1 (en) Novel crystalline forms
GEP20207158B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2021007184A (es) Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2023010882A (es) Compuestos y composiciones para el tratamiento de trastornos hematológicos.
MX2022011896A (es) Composiciones oftalmicas.
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
MX2017010348A (es) Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2020007562A (es) Nuevas antranilamidas, su uso como insecticida y procesos para su preparacion.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2020003185A (es) Nuevos compuestos heterociclicos.
WO2018189661A3 (en) Methods and compounds for treating diabetes
CR20210021A (es) Apirasas solubilizadas, métodos y usos
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2020013857A (es) Bacterias bifidobacterium bifidum no viables y usos de las mismas.
PH12021551091A1 (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
ZA202005083B (en) Solid forms of fasoracetam
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
MX2021014918A (es) Derivados de 3-(2-(heteroaril)-piridin-4-yl)-5-(trifluorometil)-1, 2,4-oxadiazol como inhibidores de hdac6.
EA202090432A1 (ru) Новые соединения, активирующие путь nrf2